The Library

Circadian oscillation of circulating prothrombotic thrombospondin-1 : ex vivo and in vivo regulation by insulin

Tools

Tan, Bee K., Syed, Farhatullah, Lewandowski, K. C., O'Hare, J. Paul and Randeva, Harpal S. (2008) Circadian oscillation of circulating prothrombotic thrombospondin-1 : ex vivo and in vivo regulation by insulin. Journal of Thrombosis and Haemostasis, Vol.6 (No.10). pp. 1827-1830. ISSN 1538-7933

Full text not available from this repository.
Item Type: Journal Item
Subjects: Q Science > QP Physiology
R Medicine > RC Internal medicine
Divisions: Faculty of Medicine > Warwick Medical School > Clinical Sciences Research Institute (CSRI)
Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Circadian rhythms, Insulin, Metabolic syndrome
Journal or Publication Title: Journal of Thrombosis and Haemostasis
Publisher: Wiley-Blackwell Publishing Ltd.
ISSN: 1538-7933
Date: October 2008
Volume: Vol.6
Number: No.10
Number of Pages: 4
Page Range: pp. 1827-1830
Identification Number: 10.1111/j.1538-7836.2008.03123.x
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: Heart Research (UK)
References: 1 Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457–62. 2 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548–56. 3 Alessi MC, Peiretti F, Morange P,Henry M, NalboneG, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860–7. 4 Varma V, Yao-Borengasser A, Bodles AM, Rasouli N, Phanavanh B, Nolen GT, Kern EM, Nagarajan R, Spencer HJ III, Lee MJ, Fried SK,McGehee RE Jr, Peterson CA,Kern PA. Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes 2008; 57: 432–9. 5 McLaren KM. Immunohistochemical localisation of thrombospondin in human megakaryocytes and platelets. J Clin Pathol 1983; 36: 197–9. 6 Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 2001; 107: 929–34. 7 Esemuede N, Lee T, Pierre-Paul D, Sumpio BE, Gahtan V. The role of thrombospondin-1 in human disease. J Surg Res 2004; 122: 135–42. 8 Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998; 93: 1159–70. 9 Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M, Geel O, Juhan-Vague I. Plasminogen activator inhibitor 1, transforming growth factor-b1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49: 1374–80. 10 Samad F, Yamamoto K, Pandey M, Loskutoff DJ. Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med 1997; 3: 37–48. 11 Mertens I, Verrijken A, Michiels JJ, Van der Planken M,Ruige JB, van Gaal LF. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006; 30: 1308–14. 12 O�Hare P. The effects of volume expansion on renal function in insulin dependent diabetes mellitus. MD thesis, London: Guy’s Hospital, University of London, 1985. 13 Fried SK, Moustaid-Moussa N. Culture of adipose tissue and isolated adipocytes. Methods Mol Biol 2001; 155: 197–212. 14 Bayraktar M, Dundar S, Kirazli S, Teletar F. Platelet factor 4, betathromboglobulin and thrombospondin levels in type I diabetes mellitus patients. J IntMed Res 1994; 22: 90–4. 15 Tschoepe D, Rauch U, Schwippert B. Platelet-leukocyte-cross-talk in diabetes mellitus. Horm Metab Res 1997; 29: 631–5. 16 Olson BA, Day JR, Laping NJ. Age-related expression of renal thrombospondin 1 mRNA in F344 rats: resemblance to diabetes-induced expression in obese Zucker rats. Pharmacology 1999; 58: 200–8. 17 Poczatek MH, Hugo C, Darley-Usmar V, Murphy-Ullrich JE. Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol 2000; 157: 1353–63. 18 Stegenga ME, van der Crabben SN, LeviM, de Vos AF, Tanck MW, Sauerwein HP, van der Poll T. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006; 55: 1807–12. 19 Juhan-Vague I, Morange PE, Alessi MC. The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. Pathophysiol Haemost Thromb 2002; 32: 269–73. 20 van der Bom JG, Bots ML, Haverkate F, Kluft C, Grobbee DE. The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood 2003; 101: 1841–4. 21 Angleton P, ChandlerWL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79: 101–6. 22 Muller JE, StonePH, Turi ZG,Rutherford JD, Czeisler CA,ParkerC, Poole WK, Passamani E, Roberts R, Robertson T, Sobel BE, Willerson JT, Braunwauld E, the MILIS Study Group. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315–22. 23 Marler JR, Price TR, Clark GL, Muller JE, Robertson T, Mohr JP, Hier DB, Wolf PA, Caplan LR, Foulkes MA. Morning increase in onset of ischemic stroke. Stroke 1989; 20: 473–6.
URI: http://wrap.warwick.ac.uk/id/eprint/29329

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item View Item